ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 489

S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)

Adéla Navrátilová1, Jiří Baloun 2, Hana Hulejová 2, Karel Pavelka 3, Jiří Vencovský 3, Ladislav Senolt 3 and Lucie Andrés Cerezo 1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Neutrophil Extracellular Traps, rheumatoid arthritis (RA) and inflammation

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: S100A11 protein, a member of S100 family, has been associated with several autoimmune inflammatory conditions such as rheumatoid arthritis (RA). Moreover, its pro-inflammatory effect on mononuclear cells has been reported (1). Although the pathogenesis of autoimmune diseases is not fully understood, the formation of NETs seem to play a certain role. Recent data indicate that some DAMPs including S100A8/A9 are released via NETosis and can further augment inflammatory responses.

Methods: To assess the expression of S100A11 by neutrophils of RA synovial tissue (n=5), immunofluorescence staining of S100A11 and myeloperoxidase (MPO) was performed. The levels of S100A11 and MPO in RA synovial fluid (n=24) and serum (n=36) were measured by ELISAs (RayBiotech and Abcam). For in vitro experiments, NETosis was induced by adding phorbol 12-myristate 13-acetate (PMA) to the neutrophils purified from peripheral blood of RA patients (n=7). Release of NETs was visualised by immunocytochemistry (n=4-7) and the presence of S100A11 in supernatants was analysed by ELISA (RayBiotech). Neutrophils purified from healthy donors were stimulated by S100A11 and the release of cytokines TNFα, IL-6 was measured by ELISA (RayBiotech).

Results: S100A11 was expressed by synovial tissue neutrophils of the RA patients (n=5). The levels of S100A11 in the serum and in the synovial fluid of patients with RA were significantly associated with the levels of neutrophil MPO (r=0.463, p=0.005 and r=0.500, p=0.013). We demonstrated that the neutrophils treated by LPS (n=7) did not up-regulate the secretion of S100A11 compared to unstimulated controls (0.28±0.07 vs. 0.25±0.06; p=ns). However, the release of S100A11 was significantly up-regulated in PMA stimulated neutrophils undergoing NETosis compared to untreated controls (0.30±0.08 vs. 1.14±0.22; p=0.006). Moreover, our results showed that DPI treatment abolished PMA-induced S100A11 secretion. By immunofluorescence staining we demonstrated that the neutrophils activated by PMA release NETs containing S100A11 protein whereas cells stimulated by DPI+PMA were not able to form NETs. In addition, extracellular S100A11 did not modulate the secretion of pro-inflammatory cytokines TNFα and IL-6 by human neutrophils (n=5).

Conclusion: Here we show for the first time that the release of S100A11 by neutrophils could be dependent on NETosis. Moreover, extracellular S100A11 does not further augment the inflammatory response of neutrophils in RA.

Acknowledgement: Supported by MHCR 023728 and SVV – 260373
References: (1) Andrés Cerezo et al., Arthritis Research & Therapy (2017) 19:79, DOI 10.1186/s13075-017-1288-y


Disclosure: A. Navrátilová, None; J. Baloun, None; H. Hulejová, None; K. Pavelka, AbbVie, 8, Abbvie, 5, 8, Amgen, 5, 8, BMS, 8, Egis, 5, 8, Lilly, 5, 8, MSD, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 8; J. Vencovský, projeMinistry of Health, Czech Republic, project 00023728, 2; L. Senolt, None; L. Andrés Cerezo, None.

To cite this abstract in AMA style:

Navrátilová A, Baloun J, Hulejová H, Pavelka K, Vencovský J, Senolt L, Andrés Cerezo L. S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/s100a11-calgizzarin-is-released-during-neutrophil-extracellular-traps-nets-formation-in-rheumatoid-arthritis-ra/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/s100a11-calgizzarin-is-released-during-neutrophil-extracellular-traps-nets-formation-in-rheumatoid-arthritis-ra/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology